Rabbit Recombinant Monoclonal JAK2 phospho Y1007 + Y1008 and JAK1 phospho Y1034 + Y1035 antibody - conjugated to Alexa Fluor® 555.
pH: 7.4
Preservative: 0.02% Sodium azide
Constituents: 68% PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
Application | Reactivity | Dilution info | Notes |
---|---|---|---|
Application Target Binding Affinity | Reactivity Expected | Dilution info - | Notes - |
Application Antibody Labelling | Reactivity Expected | Dilution info - | Notes - |
Select an associated product type
Non-receptor tyrosine kinase involved in various processes such as cell growth, development, differentiation or histone modifications. Mediates essential signaling events in both innate and adaptive immunity. In the cytoplasm, plays a pivotal role in signal transduction via its association with type I receptors such as growth hormone (GHR), prolactin (PRLR), leptin (LEPR), erythropoietin (EPOR), thrombopoietin receptor (MPL/TPOR); or type II receptors including IFN-alpha, IFN-beta, IFN-gamma and multiple interleukins (PubMed:15690087, PubMed:7615558, PubMed:9657743, PubMed:15899890). Following ligand-binding to cell surface receptors, phosphorylates specific tyrosine residues on the cytoplasmic tails of the receptor, creating docking sites for STATs proteins (PubMed:15690087, PubMed:9618263). Subsequently, phosphorylates the STATs proteins once they are recruited to the receptor. Phosphorylated STATs then form homodimer or heterodimers and translocate to the nucleus to activate gene transcription. For example, cell stimulation with erythropoietin (EPO) during erythropoiesis leads to JAK2 autophosphorylation, activation, and its association with erythropoietin receptor (EPOR) that becomes phosphorylated in its cytoplasmic domain (PubMed:9657743). Then, STAT5 (STAT5A or STAT5B) is recruited, phosphorylated and activated by JAK2. Once activated, dimerized STAT5 translocates into the nucleus and promotes the transcription of several essential genes involved in the modulation of erythropoiesis. Part of a signaling cascade that is activated by increased cellular retinol and that leads to the activation of STAT5 (STAT5A or STAT5B) (PubMed:21368206). In addition, JAK2 mediates angiotensin-2-induced ARHGEF1 phosphorylation (PubMed:20098430). Plays a role in cell cycle by phosphorylating CDKN1B (PubMed:21423214). Cooperates with TEC through reciprocal phosphorylation to mediate cytokine-driven activation of FOS transcription. In the nucleus, plays a key role in chromatin by specifically mediating phosphorylation of 'Tyr-41' of histone H3 (H3Y41ph), a specific tag that promotes exclusion of CBX5 (HP1 alpha) from chromatin (PubMed:19783980). Up-regulates the potassium voltage-gated channel activity of KCNA3 (PubMed:25644777).
JAK1 phospho Y1034 + Y1035
Tyrosine-protein kinase JAK2, Janus kinase 2, JAK-2, JAK2
Rabbit Recombinant Monoclonal JAK2 phospho Y1007 + Y1008 and JAK1 phospho Y1034 + Y1035 antibody - conjugated to Alexa Fluor® 555.
pH: 7.4
Preservative: 0.02% Sodium azide
Constituents: 68% PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
This antibody is phospho-specific and only detects phosphorylated JAK2 on Tyrosine 1007 and 1008 (pY1007+Y1008) and JAK1 on Tyrosine 1034 and 1035 (pY1034+Y1035). According to our ELISA results, this antibody preferentially recognizes phospho Y1007. Stimulation may be required to allow detection of the phosphorylated protein. Please see images below for recommended treatment conditions and positive controls. The mouse and rat recommendation is based on the WB results. We do not guarantee IHC-P for mouse and rat.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone. This conjugated antibody is eligible for the Abcam trial program.
JAK2 also known as Janus kinase 2 is a protein tyrosine kinase with a molecular weight of 125 kDa. It plays an essential mechanical role in the signaling pathways by acting as an intermediary between cell surface receptors and intracellular signaling molecules. The JAK2 protein binds to certain cytokine receptors facilitating signal transduction necessary for various cellular responses. JAK2 is expressed in many tissues including hematopoietic cells which are associated with the blood and immune systems.
JAK2 is important for transmitting signals that dictate cell growth survival and differentiation within the hematopoietic system. It operates bodily functions by forming complexes with specific phosphorylation sites on its associated receptors. Through this formation JAK2 influences the signaling cascade particularly by interacting with other signal transducers and activators where it phosphorylates and becomes activated. This action affects gene transcription directly correlated with cellular proliferation and differentiation processes.
The function of JAK2 integrates into the JAK-STAT signaling pathway which is an important pathway in the regulation of immune function growth and development. It works in conjunction with proteins such as STAT3 and STAT5 to transmit signals from cytokine receptors to the nucleus. This pathway critically impacts responses like inflammation and hematopoiesis aligning with its role in precursor proliferation within the bone marrow and various immune cells’ function.
JAK2 has significant implications in conditions like myeloproliferative neoplasms and polycythemia vera. Mutations in the JAK2 gene notably the JAK2 V617F mutation lead to uncontrolled cell division as they disrupt normal signaling mechanisms often resulting in blood cell disorders. In these contexts JAK2 interacts with proteins such as EpoR and MPL which play roles within these disease pathways. Understanding how JAK2 mutations contribute to disease progression offers pathways for targeted therapies.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
This data was developed using the same antibody clone in a different buffer formulation (Anti-JAK2 (phospho Y1007 + Y1008) + Anti-JAK1 (phospho Y1034 + Y1035) antibody [E132] ab32101).
Blocking and dilution buffer: 5% NFDM /TBST.
All lanes: Western blot - Anti-JAK2 (phospho Y1007 + Y1008) + Anti-JAK1 (phospho Y1034 + Y1035) antibody [E132] (Anti-JAK2 (phospho Y1007 + Y1008) + Anti-JAK1 (phospho Y1034 + Y1035) antibody [E132] ab32101) at 1/1000 dilution
Lane 1: 293T cells transfected with a Human JAK1 expression vector containing a His tag whole cell lysate at 20 µg
Lane 2: 293T cells transfected with a Human JAK1 expression vector containing a His tag were treated with 50uM pervanadate for 30 min whole cell lysate at 20 µg
Lane 3: 293T cells transfected with a Human JAK1 (mutated Y1034A, mutated Y1035A) expression vector containing a His tag whole cell lysate at 20 µg
Lane 4: 293T cells transfected with a Human JAK1 (mutated Y1034A, mutated Y1035A) expression vector containing a His tag were treated with 50uM pervanadate for 30 min whole cell lysate at 20 µg
Lane 5: 293T cells transfected with a Human JAK2 expression vector containing a His tag whole cell lysate at 20 µg
Lane 6: 293T cells transfected with a Human JAK2 expression vector containing a His tag were treated with 50uM pervanadate for 30 min whole cell lysate at 20 µg
Lane 7: 293T cells transfected with a Human JAK2 (mutated Y1007A, mutated Y1008A) expression vector containing a His tag whole cell lysate at 20 µg
Lane 8: 293T cells transfected with a Human JAK2 (mutated Y1007A, mutated Y1008A) expression vector containing a His tag were treated with 50uM pervanadate for 30 min whole cell lysate at 20 µg
All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/20000 dilution
Performed under reducing conditions.
Observed band size: 130 kDa
Exposure time: 7s
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com